Primary drug resistance is an emerging problem in HIV infections. We have investigated the current prevalence of primary resistance in Korea and compared it with previous data. Drug-naive HIV patients attending the outpatient clinic of Seoul National University Hospital between April and August 2006 were enrolled. A medical interview and a genotypic resistance test were performed for each patient. The International AIDS Society-USA Panel consensus statement issued in 2006 was used to define resistance mutations. Eighty-one drug-naive HIV patients were enrolled. Two (2.5%) were infected with primary drug-resistant virus: M41L and K103N, respectively. In our previous study, conducted between 1998 and 2002, three (6%) of 50 subjects harbored resistant viruses. Thus the frequency of primary resistance was lower in the present sample than in the earlier one, though the difference is not statistically significant (p ‫؍‬ 0.37). In view of our findings, routine antiretroviral resistance tests for drug-naive HIV patients are not obligatory in Korea. 83 
I
N KOREA, zidovudine alone or a combination of two nucleoside analog reverse transcriptase inhibitors (NRTIs) was prescribed to HIV patients until the introduction of highly active antiretroviral therapy (HAART) in the late 1990s. As a consequence, incomplete viral suppression and the induction of antiretroviral resistance were common among the patients who had been treated before the introduction of HAART. We have reported the prevalence of primary drug resistance in 50 drugnaive patients who attended Seoul National University Hospital (SNUH) between 1998 and 2002. 1 In that study, the prevalence of primary resistance was 8.0%: but it would be 6.0% on the basis of the current consensus developed in 2006. 2 Currently HAART is widely employed in Korea and the prevalence of antiretroviral drug resistance in drug-naive patients may have changed. We have investigated the current prevalence of antiretroviral resistance in drug-naive Korean patients.
Drug-naive HIV patients who visited the outpatient clinic of SNUH between April and August 2006 were enrolled. Medical interviews and reviews of medical records were carried out to obtain clinical information, and peripheral blood was taken to assess the genotypic resistance of the HIV of each patient.
The ViroSeq HIV-1 Genotyping System v2.5 (Celera Diagnostics, Alameda, CA), which was designed to analyze the pol gene of HIV-1, was used to sequence plasma HIVs. The IAS-USA Drug Resistance Mutations Group consensus issued in 2006 was employed to decide whether the sequences contained resistance mutations. 2 Only major mutations were included for protease inhibitors (PIs). The REGA HIV subtyping tool v2.0 (http://dbpartners.stanford.edu/RegaSubtyping/) was used to identify virus subtypes.
We compared the current prevalence of primary antiretroviral resistance with our previous data. 1 In the previous study, 50 preserved HIV-infected patient plasmas were used to test for resistance and clinical data were acquired retrospectively.
Eighty-one patients were enrolled during the present study period. All were male and infected by sexual intercourse. Table  1 presents the clinical features of the subjects. All the patients were infected with HIV-1 subtype B, except two who were infected with HIV-1 subtype CRF01_AE and subtype C, respectively. Two (2.5%) of the 81 subjects had resistant mutations. Among the nucleoside reverse transcriptase inhibitor (NRTI) resistance mutations, we identified one case of a M41L mutation. As for nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance, one case of K103N was identified and there were no PI resistance mutations (Table 2) . Six patients had the V118I mutation and none had the E44D mutation. These two mutations were classified as resistance mutations in the previous version of the IAS-USA panel consensus but not in the 2006 version. 2 As mentioned above, in our previous study 3 of the 50 subjects (6%) had resistant viruses including one multiclass resistant case (Table 2) .
Recent studies in the United States and Europe have indicated that 10-20% of new HIV infections are resistant. [3] [4] [5] [6] [7] [8] [9] Even making allowance for the recent change of classification of drug resistance mutations by the IAS-USA panel, we can be confident that the prevalence of primary resistance in Korea is lower than in the United States and Europe. The IAS-USA panel recommends genotypic resistance tests for drug-naive patients when the prevalence of primary drug resistance is more than 5%. 10 In view of the outcome of the current study, routine resistance tests for drug-naive patients are not obligatory in Korea.
According to a mathematical model proposed by Maria et al., a decrease in primary HIV resistance could be a result of three processes: an increase in high-risk behavior, a decrease in the fraction of acute treated patients, or an increase in treatment efficacy. 11 Currently HAART is widely employed in Korea. Thus a change in treatment efficacy might have some influence on changes of the prevalence of primary antiretroviral drug resistance, but additional studies are required.
In conclusion, the current prevalence of primary drug resistance in drug-naive HIV-infected patients in Korea is 2.5%. Therefore routine genotypic resistance testing of drug-naive HIV patients is not obligatory.
The nucleotide sequences obtained in our study are now available in GenBank with accession numbers EF157857-EF157937. 
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